Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGelion Regulatory News (GELN)

Share Price Information for Gelion (GELN)

Share Price is delayed by 15 minutes
Get Live Data
19.25    0.00 (0.00%)
Bid:
18.50
Ask:
20.00
Spread: 1.50 (8.108%)
Market Cap: £44.16m
GELN Live PriceLast checked at - London Stock Exchange

Intraday Gelion Share Chart

Expanded Li-S R&D Facility launched

11 Oct 2023 07:00

RNS Number : 7632P
Gelion PLC
11 October 2023

REACH

11 October 2023

Gelion plc

("Gelion" or the "Company" or the "Group")

Expanded Li-S R&D Facility launched to enable prototyping toward commercial cell development

Gelion (AIM: GELN), the Anglo-Australian battery innovator, announces new Lithium-Sulfur (Li-S) Research and Development (R&D) Facility designed to optimise development and accelerate market readiness of this technology by producing more advanced cell prototypes.

Based in Sydney, adjacent to Gelion's research and corporate office, the facility will allow the Company to advance prototyping toward cell development and to capitalise on the combination of Gelion's existing technologies with the intellectual property (IP) packages acquired from Johnson Matthey in March 2023.

Having achieved technical progress with sulfur cathode chemistry, this facility will enable Gelion to build multi-layer pouch cells (a soft battery design where battery components are enclosed in a pouch casing, like in a mobile phone or laptop), which are the industry standard for testing batteries and the form factor used for customer off-take.

The new facility is another milestone as Gelion continues to deliver against its go-to-market strategy and will bring a multitude of benefits to the Group, including:

·

enabling researchers to more rapidly test promising research in multi-layer pouch cells;

·

enabling Gelion to effectively participate in joint development agreements with anode developers; and

·

enable the production of prototypes that can be supplied for preliminary third-party validation and safety testing.

The prototypes produced will be multi-layer pouch cells and further focused product development ahead of offtake with partners. The prototypes will also inform TRL 4 (Technology Readiness Levels) and are a key commercial proof point for Gelion's technology. The facility and its output will help underpin the winning of contracts and subsequent scale up to commercial manufacture.

Commenting on the new facility, John Wood, CEO said:

"The site has the capability to increase Gelion's prototyping toward cell development and the progressive commissioning of the capability commenced in late September 2023. The opening of this facility further evidences the steady progress Gelion is making on its path to commercialisation. We are incredibly excited to be opening this research and development facility to increase capacity to ensure we optimise development of Lithium Sulfur for the rapidly expanding market.

"Lithium-Sulfur is the next generation for electric mobility and has the potential to power the future of transport. Gelion has built a large IP moat, and, with its highly skilled team of specialists, we are working towards our goal of delivering commercially viable and scalable, next generation battery chemistries."

CONTACTS

Gelion plc

John Wood, CEO

Amit Gupta, CFO

Thomas Maschmeyer, Founder and Principal Technology Advisor

via Alma PR

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

+44 207 220 0500

Corporate Finance

Neil McDonald

Seamus Fricker

Fergus Sullivan

ECM

Barney Hayward

Alma PR (Financial PR Adviser)

Justine James

Hannah Campbell

Will Ellis Hancock

+44 20 3405 0205

gelion@almapr.co.uk

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAGUBDGRXBDGXB
Date   Source Headline
4th Jun 202612:53 pmRNS-RPublication of Research Report
2nd Jun 20267:00 amRNSNissan Project, Grant Award, Investor Presentation
21st May 20267:00 amRNSHolding(s) in Company
13th Apr 20267:00 amRNS-RQ1 2026 Newsletter
31st Mar 20267:00 amRNSExceptional Technical Results
3rd Mar 20268:32 amRNSDirector/PDMR Shareholding - Grant of options
2nd Mar 20267:00 amRNSHalf year results to 31 December 2025
11th Feb 20267:00 amRNSBusiness Update, Notice of Results & IMC
4th Feb 20267:00 amRNSChange of Registered Office
27th Jan 20268:02 amRNSBlock Admission Return
15th Jan 20267:00 amRNSProf. Rachid Yazami Appointed Technology Advisor
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
24th Dec 20259:24 amRNSDirector Dealing
24th Dec 20259:24 amRNSDirector Dealing
22nd Dec 202512:18 pmRNSResult of AGM
22nd Dec 202512:18 pmRNSResult of AGM
11th Dec 20257:00 amRNS-RChange of Name of OXLiD Ltd to Gelion Europe Ltd
10th Dec 20258:59 amRNSDirector/PDMR Shareholding - Grant of Options
4th Dec 20257:00 amRNSGelion Achieves Key Industry Technical Milestone
27th Nov 20257:01 amRNSNotice of AGM
27th Nov 20257:00 amRNSFinal results to 30 June 2025
25th Nov 20258:30 amRNSNotice of Results and Investor Presentation
5th Nov 20259:21 amRNSResult of GM, PDMR Dealings & Total Voting Rights
29th Oct 20257:00 amRNS-RGeneral Meeting Information
21st Oct 20257:00 amRNSResult of Oversubscribed WRAP Retail Offer
21st Oct 20257:00 amRNSFull Collaboration Agreement with TDK
20th Oct 20254:30 pmRNSEarly Close of WRAP Retail Offer
17th Oct 202510:34 amRNSResult of Placing and Subscription
16th Oct 20255:30 pmRNSWRAP Retail Offer for up to £500k
16th Oct 20254:43 pmRNSProposed Placing, Subscription & Retail Offer
16th Oct 20254:35 pmRNSThree Li-S Patents Advance Successfully in U.S.
16th Oct 20254:35 pmRNSSulfur CAM: Drop-In for Existing Battery Plants
16th Oct 20254:35 pmRNSCollaboration with Tier-One Battery Partner
19th Sep 20257:30 amRNSOXLiD funding for Li-S project with QinetiQ
15th Sep 20257:00 amRNSHigh Lithium Recovery at Battery Minerals Ltd
3rd Sep 20257:00 amRNSSuccessful MPI Tech Transfer & Sulfur CAM Scale-Up
5th Aug 20257:00 amRNSGelion Achieves Breakthrough in Li-S Performance
1st Aug 20257:00 amRNSNotification of Major Holdings
28th Jul 20257:00 amRNSBlock Admission Return
14th Jul 20257:00 amRNSGrant Funding & Commissioning of Prototyping Line
8th Jul 20257:00 amRNSCommencement of £2.3m Australian Government Grant
1st Jul 20257:00 amRNSSuccessful Installation of 4-MWh BESS
26th Jun 20257:07 amRNSStrong Progress at Battery Minerals
5th Jun 20259:16 amRNSHolding(s) in Company
5th Jun 20259:15 amRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDirector Holdings
20th May 20257:00 amRNSDirector Dealing
6th May 20254:07 pmRNSResult of GM, PDMR Dealings & Total Voting Rights
30th Apr 202511:42 amRNSDirector/PDMR Shareholding - Grant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.